Cargando…
Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. Several recent findings that there are activating mutations in the KIT and PDGFRA (platelet-derived growth factor receptor-α) genes of GISTs provide the rationale for using targeted therapies...
Autores principales: | Kim, Hyo-Sin, Kim, Sung-Soo, Park, Sang-Gon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Surgical Society
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996717/ https://www.ncbi.nlm.nih.gov/pubmed/24783183 http://dx.doi.org/10.4174/astr.2014.86.4.220 |
Ejemplares similares
-
Recurring gastrointestinal stromal tumor with splenic metastasis
por: Kim, Ho Gun, et al.
Publicado: (2011) -
Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives
por: Mulet-Margalef, Nuria, et al.
Publicado: (2016) -
Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors
por: Khosravan, Reza, et al.
Publicado: (2021) -
Pneumatosis Cystoides Intestinalis Secondary to Sunitinib Treatment for Gastrointestinal Stromal Tumor
por: Asahi, Yoh, et al.
Publicado: (2018) -
Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
por: Tielen, Ronald, et al.
Publicado: (2012)